fluorouracil has been researched along with Cardiac Failure in 54 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epirubicin-based chemotherapy improves the outcome of early breast cancer (BC) patients." | 9.20 | Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. ( Aftimos, P; Ameye, L; Beauduin, M; Bejarano Hernández, S; Cornez, N; de Azambuja, E; Delhaye, F; Diaz, M; Focan, C; Lemort, M; Paesmans, M; Piccart-Gebhart, M; Shih-Li, C; Suter, T; Vandenbossche, S; Vindevoghel, A, 2015) |
| "PURPOSE To evaluate long-term cardiac function in patients without disease who had received six cycles of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC 50) or the same regimen with epirubicin 100 mg/m(2) (FEC 100) as adjuvant chemotherapy for node-positive breast cancer in the French Adjuvant Study Group-05 trial." | 9.11 | Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. ( Barats, JC; Bonneterre, J; Chapelle-Marcillac, I; Clavère, P; Datchary, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Roché, H; Van Praagh, I; Veyret, C, 2004) |
| " We conducted a Phase II trial of an anthracycline analogue, pirarubicin, administered in combination with 5-fluorouracil and cyclophosphamide every 3 weeks, as front-line chemotherapy in women with metastatic breast cancer." | 9.08 | Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ( Buzdar, A; Dhingra, K; Fraschini, G; Frye, D; Hortobagyi, GN; Newman, RA; Smith, T; Theriault, R; Walters, R, 1995) |
| "To assess whether dexrazoxane (DZR) given after a cumulative doxorubicin dose of 300 mg/m2 confers cardioprotection in patients with advanced breast cancer treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC)." | 9.08 | Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. ( Bianchine, JR; Ewer, MS; Gams, RA; Gerber, MC; Swain, SM; Whaley, FS, 1997) |
| "To determine the cardioprotective effect of dexrazoxane (DZR) used in a doxorubicin-based combination therapy in advanced breast cancer." | 9.08 | Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. ( Bianchine, JR; Desai, A; Ewer, MS; Gams, RA; Gerber, MC; Jones, SE; Mittelman, A; Pendergrass, K; Reddy, S; Speyer, J; Spicer, D; Swain, SM; Velez-Garcia, E; Vogel, C; Wadler, S; Weisberg, S; Whaley, FS; York, M, 1997) |
| "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients." | 9.07 | A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991) |
| "To improve current adjuvant results in high-risk breast cancer, in February 1982 we activated a prospective randomized trial using both intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) and Adriamycin (doxorubicin; Farmitalia-Carlo Erba, Milan, Italy) involving patients with resectable mammary carcinoma and more than three positive axillary lymph nodes." | 9.07 | Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. ( Bonadonna, G; Buzzoni, R; Valagussa, P; Zambetti, M, 1991) |
| "A 69-year-old woman presented with arterial hypotension, pulmonary oedema and a severely depressed left ventricular ejection fraction (LVEF) of 25% only 3 days after having received her first treatment for colorectal cancer with 5-fluorouracil (5-FU)-based therapy." | 7.83 | 5-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI. ( Dalsgaard, M; Fakhri, Y; Lav Madsen, P; Nielsen, D, 2016) |
| " We aimed to examine whether heart failure or impairment could be demonstrated several years after low-dose epirubicin-based adjuvant treatment." | 7.78 | Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer. ( Appel, JM; Christensen, HM; Ejlertsen, B; Fogh-Andersen, N; Jensen, BV; Møller, S; Nielsen, DL; Søgaard, P; Zerahn, B, 2012) |
| "A case of acute heart failure due to Takotsubo cardiomyopathy induced by 5-fluorouracil is described." | 7.75 | A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. ( Hata, N; Kobayashi, N; Mizuno, K; Shinada, T; Shirakabe, A; Yokoyama, S, 2009) |
| "Data were collected from 1097 consecutive anthracycline-naive patients treated for metastatic breast cancer with epirubicin." | 7.74 | New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. ( Andersen, PK; Cortese, G; Nielsen, D; Nielsen, G; Ryberg, M; Skovsgaard, T, 2008) |
| "Intravenous 5-fluorouracil in combination with low doses of folinic acid can induce severe nonischemic heart failure." | 7.70 | Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump. ( David, JS; Gaussorgues, P; Gueugniaud, PY; Hepp, A; Petit, P, 2000) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 6.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| "To investigate cardiac toxicity associated with breast radiation therapy (RT) at 10-year follow-up in BCIRG-001, a phase 3 trial comparing adjuvant anthracycline chemotherapy (fluorouracil, doxorubicin, and cyclophosphamide) with anthracycline-taxane chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) in women with lymph node-positive early breast cancer." | 5.24 | Effect of Breast Irradiation on Cardiac Disease in Women Enrolled in BCIRG-001 at 10-Year Follow-Up. ( Gerber, NK; Perez, CA; Tam, M; Vega, RM; Wu, SP, 2017) |
| "Epirubicin-based chemotherapy improves the outcome of early breast cancer (BC) patients." | 5.20 | Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. ( Aftimos, P; Ameye, L; Beauduin, M; Bejarano Hernández, S; Cornez, N; de Azambuja, E; Delhaye, F; Diaz, M; Focan, C; Lemort, M; Paesmans, M; Piccart-Gebhart, M; Shih-Li, C; Suter, T; Vandenbossche, S; Vindevoghel, A, 2015) |
| "PURPOSE To evaluate long-term cardiac function in patients without disease who had received six cycles of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC 50) or the same regimen with epirubicin 100 mg/m(2) (FEC 100) as adjuvant chemotherapy for node-positive breast cancer in the French Adjuvant Study Group-05 trial." | 5.11 | Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. ( Barats, JC; Bonneterre, J; Chapelle-Marcillac, I; Clavère, P; Datchary, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Roché, H; Van Praagh, I; Veyret, C, 2004) |
| " We conducted a Phase II trial of an anthracycline analogue, pirarubicin, administered in combination with 5-fluorouracil and cyclophosphamide every 3 weeks, as front-line chemotherapy in women with metastatic breast cancer." | 5.08 | Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ( Buzdar, A; Dhingra, K; Fraschini, G; Frye, D; Hortobagyi, GN; Newman, RA; Smith, T; Theriault, R; Walters, R, 1995) |
| "To assess whether dexrazoxane (DZR) given after a cumulative doxorubicin dose of 300 mg/m2 confers cardioprotection in patients with advanced breast cancer treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC)." | 5.08 | Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. ( Bianchine, JR; Ewer, MS; Gams, RA; Gerber, MC; Swain, SM; Whaley, FS, 1997) |
| "To determine the cardioprotective effect of dexrazoxane (DZR) used in a doxorubicin-based combination therapy in advanced breast cancer." | 5.08 | Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. ( Bianchine, JR; Desai, A; Ewer, MS; Gams, RA; Gerber, MC; Jones, SE; Mittelman, A; Pendergrass, K; Reddy, S; Speyer, J; Spicer, D; Swain, SM; Velez-Garcia, E; Vogel, C; Wadler, S; Weisberg, S; Whaley, FS; York, M, 1997) |
| "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients." | 5.07 | A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991) |
| "To improve current adjuvant results in high-risk breast cancer, in February 1982 we activated a prospective randomized trial using both intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) and Adriamycin (doxorubicin; Farmitalia-Carlo Erba, Milan, Italy) involving patients with resectable mammary carcinoma and more than three positive axillary lymph nodes." | 5.07 | Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. ( Bonadonna, G; Buzzoni, R; Valagussa, P; Zambetti, M, 1991) |
| " In a randomized trial in 92 women with advanced breast cancer, we compared treatment with fluorouracil, doxorubicin, and cyclophosphamide (FDC), given every 21 days, with the same regimen preceded by administration of ICRF-187 (FDC + ICRF-187)." | 5.06 | Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. ( Dubin, N; Ferrans, V; Green, MD; Kramer, E; Rey, M; Sanger, J; Speyer, JL; Stecy, P; Ward, C; Zeleniuch-Jacquotte, A, 1988) |
| "A 69-year-old woman presented with arterial hypotension, pulmonary oedema and a severely depressed left ventricular ejection fraction (LVEF) of 25% only 3 days after having received her first treatment for colorectal cancer with 5-fluorouracil (5-FU)-based therapy." | 3.83 | 5-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI. ( Dalsgaard, M; Fakhri, Y; Lav Madsen, P; Nielsen, D, 2016) |
| " We aimed to examine whether heart failure or impairment could be demonstrated several years after low-dose epirubicin-based adjuvant treatment." | 3.78 | Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer. ( Appel, JM; Christensen, HM; Ejlertsen, B; Fogh-Andersen, N; Jensen, BV; Møller, S; Nielsen, DL; Søgaard, P; Zerahn, B, 2012) |
| "A case of acute heart failure due to Takotsubo cardiomyopathy induced by 5-fluorouracil is described." | 3.75 | A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. ( Hata, N; Kobayashi, N; Mizuno, K; Shinada, T; Shirakabe, A; Yokoyama, S, 2009) |
| "Data were collected from 1097 consecutive anthracycline-naive patients treated for metastatic breast cancer with epirubicin." | 3.74 | New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. ( Andersen, PK; Cortese, G; Nielsen, D; Nielsen, G; Ryberg, M; Skovsgaard, T, 2008) |
| "Intravenous 5-fluorouracil in combination with low doses of folinic acid can induce severe nonischemic heart failure." | 3.70 | Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump. ( David, JS; Gaussorgues, P; Gueugniaud, PY; Hepp, A; Petit, P, 2000) |
| "A study of cardioprotection with ICRF-187 (Cardioxane, Eurocetus) has been performed in 35 patients with metastatic breast cancer treated with the FDC regimen (5-fluorouracil 500 mg/m2 i." | 3.69 | Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen. ( Bosnjak, S; Jelić, S; Kreacić, M; Milanović, N; Nesković-Konstantinović, Z; Radulović, S; Ristović, Z; Vuletić, L, 1995) |
| " Nine patients had symptoms resembling myocardial ischemia, one patient died due to assumed myocardial infarction related closely to fluorouracil treatment, four patients had supraventricular arrhythmia, and one patient had congestive heart failure." | 3.68 | Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. ( Bokemeyer, C; Harstrick, A; Hiddemann, W; Köhne-Wömpner, CH; Mügge, A; Papageorgiou, E; Poliwoda, H; Schöber, C; Stahl, M; Wilke, H, 1993) |
| "Two hundred twenty-two patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adrimycin), cyclophosphamide, and BCG vaccine." | 3.66 | Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. ( Blumenschein, GR; Buzdar, AU; Campos, LT; Freireich, EJ; Gehan, EA; Gutterman, JU; Hersh, EM; Hortobagyi, GN; Smith, TL; Tashima, CK; Wheeler, WL, 1979) |
| "7% of patients experienced grade 3 and 4 adverse events, respectively." | 2.80 | Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. ( Campone, M; Citron, ML; Dang, CT; Dirix, L; Gianni, L; Krop, IE; Romieu, G; Smitt, M; Suter, TM; Xu, N; Zamagni, C, 2015) |
| "Three patients (7." | 2.77 | Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. ( Horio, A; Mizuno, T; Mukai, H; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Watanabe, T; Yamamoto, Y, 2012) |
| "Patients with early breast cancer surgically treated and eligible to adjuvant chemotherapy were enrolled." | 2.76 | Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. ( Albrile, F; Biggi, A; Bobbio, M; Feola, M; Francini, A; Garrone, O; Merlano, M; Occelli, M; Visconti, G, 2011) |
| "A total of 180 breast cancer survivors from a potential sample of 1,176 patients were entered, 163 patients at 5 to 8 years and 17 additional patients at 10 to 13 years, with 93 longitudinal assessments of LVEF." | 2.73 | Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. ( Albain, KS; Dakhil, SR; Ganz, PA; Giguere, JK; Goodwin, JW; Hussey, MA; Hutchins, LF; Martino, S; Moinpour, CM; Unger, JM, 2008) |
| "Patients with HER2-positive operable breast cancer were randomly assigned to doxorubicin plus cyclophosphamide (AC) followed by either weekly paclitaxel (arm A); paclitaxel then trastuzumab (arm B); or paclitaxel plus trastuzumab then trastuzumab alone (arm C)." | 2.73 | Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. ( Dakhil, SR; Davidson, NE; Gelmon, KA; Gersh, BJ; Gralow, JR; Hudis, CA; Ingle, JN; Jaffe, AS; Kaufman, PA; Martino, S; Perez, EA; Rodeheffer, RJ; Sledge, GW; Suman, VJ; Winer, EP, 2008) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 2.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| "Mitoxantrone (Novantrone), is an anthracenedione which in preclinical studies demonstrated a spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity." | 2.66 | Mitoxantrone: an overview of safety and toxicity. ( Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985) |
| "Sixty-nine patients with advanced breast cancer treated with cytotoxic chemotherapy were randomized to receive concomitantly either norethisterone acetate (progestogen group) or a placebo (placebo group)." | 2.64 | Combined cytotoxic and progestogen therapy for advanced breast cancer. ( Begent, RH; Hayward, JL; Knight, RK; Rubens, RD; Sexton, SA, 1978) |
| "Each anticancer regimen is associated with distinct modes of heart damage, both symptomatic and asymptomatic." | 2.53 | Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. ( Cadeddu, C; Deidda, M; Demurtas, L; Madeddu, C; Mercuro, G; Piras, A; Piscopo, G; Puzzoni, M; Scartozzi, M, 2016) |
| "Many types of cancer are now curable or, if not cured, becoming a chronic illness." | 2.49 | Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. ( Carver, JR; Liu, J; Manrique, C; Steingart, RM; Yadav, N, 2013) |
| "Patients with malignancy may present with acute circulatory compromise requiring ICU monitoring and care." | 2.41 | Circulatory shock. ( Bogolioubov, A; Groeger, JS; Keefe, DL, 2001) |
| "5%) were the most common adverse drug reaction." | 1.43 | Bevacizumab safety in Japanese patients with colorectal cancer. ( Doi, T; Hatake, K; Ishihara, Y; Shirao, K; Takahashi, Y; Uetake, H, 2016) |
| "Sixty-nine patients with thoracic squamous cell carcinoma were the core of this analysis." | 1.35 | Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. ( Chin, K; Gomi, K; Ito, H; Kozuka, T; Matsuura, M; Morota, M; Oguchi, M; Yamashita, T, 2009) |
| "The incidence of 5-fluorouracil (5-FU)-related cardiotoxicity seems to be dosage and schedule dependent." | 1.33 | Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. ( Alakavuklar, MN; Barutca, S; Kundak, I; Meydan, N; Oztop, I; Yavuzsen, T; Yilmaz, U, 2005) |
| "Two percent had congestive heart failure associated with doxorubicin." | 1.27 | Early and delayed clinical cardiotoxicity of doxorubicin. ( Blumenschein, GR; Buzdar, AU; Marcus, C; Smith, TL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (24.07) | 18.7374 |
| 1990's | 10 (18.52) | 18.2507 |
| 2000's | 15 (27.78) | 29.6817 |
| 2010's | 16 (29.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, SP | 1 |
| Tam, M | 1 |
| Vega, RM | 1 |
| Perez, CA | 1 |
| Gerber, NK | 1 |
| Steingart, RM | 1 |
| Yadav, N | 1 |
| Manrique, C | 1 |
| Carver, JR | 1 |
| Liu, J | 1 |
| Yoshida, T | 1 |
| Matsui, T | 1 |
| Aoyagi, H | 1 |
| Hasegawa, K | 1 |
| Kaneko, J | 1 |
| Maejima, S | 1 |
| Isogai, J | 1 |
| Krop, IE | 1 |
| Suter, TM | 1 |
| Dang, CT | 1 |
| Dirix, L | 1 |
| Romieu, G | 1 |
| Zamagni, C | 1 |
| Citron, ML | 1 |
| Campone, M | 1 |
| Xu, N | 1 |
| Smitt, M | 1 |
| Gianni, L | 1 |
| Rateesh, S | 1 |
| Shekar, K | 1 |
| Naidoo, R | 1 |
| Mittal, D | 1 |
| Bhaskar, B | 1 |
| de Azambuja, E | 1 |
| Ameye, L | 1 |
| Diaz, M | 1 |
| Vandenbossche, S | 1 |
| Aftimos, P | 1 |
| Bejarano Hernández, S | 1 |
| Shih-Li, C | 1 |
| Delhaye, F | 1 |
| Focan, C | 1 |
| Cornez, N | 1 |
| Vindevoghel, A | 1 |
| Beauduin, M | 1 |
| Lemort, M | 1 |
| Paesmans, M | 1 |
| Suter, T | 1 |
| Piccart-Gebhart, M | 1 |
| Hatake, K | 1 |
| Doi, T | 1 |
| Uetake, H | 1 |
| Takahashi, Y | 1 |
| Ishihara, Y | 1 |
| Shirao, K | 1 |
| Boekel, NB | 1 |
| Schaapveld, M | 1 |
| Gietema, JA | 1 |
| Russell, NS | 1 |
| Poortmans, P | 1 |
| Theuws, JC | 1 |
| Schinagl, DA | 1 |
| Rietveld, DH | 1 |
| Versteegh, MI | 1 |
| Visser, O | 1 |
| Rutgers, EJ | 1 |
| Aleman, BM | 1 |
| van Leeuwen, FE | 1 |
| Fakhri, Y | 1 |
| Dalsgaard, M | 1 |
| Nielsen, D | 2 |
| Lav Madsen, P | 1 |
| Madeddu, C | 1 |
| Deidda, M | 1 |
| Piras, A | 1 |
| Cadeddu, C | 1 |
| Demurtas, L | 1 |
| Puzzoni, M | 1 |
| Piscopo, G | 1 |
| Scartozzi, M | 1 |
| Mercuro, G | 1 |
| Coccaro, M | 1 |
| Gallucci, G | 1 |
| Ryberg, M | 1 |
| Cortese, G | 1 |
| Nielsen, G | 1 |
| Skovsgaard, T | 1 |
| Andersen, PK | 1 |
| Kobayashi, N | 1 |
| Hata, N | 1 |
| Yokoyama, S | 1 |
| Shinada, T | 1 |
| Shirakabe, A | 1 |
| Mizuno, K | 1 |
| Morota, M | 1 |
| Gomi, K | 1 |
| Kozuka, T | 1 |
| Chin, K | 1 |
| Matsuura, M | 1 |
| Oguchi, M | 1 |
| Ito, H | 1 |
| Yamashita, T | 1 |
| Feola, M | 1 |
| Garrone, O | 1 |
| Occelli, M | 1 |
| Francini, A | 1 |
| Biggi, A | 1 |
| Visconti, G | 1 |
| Albrile, F | 1 |
| Bobbio, M | 1 |
| Merlano, M | 1 |
| Shipman, KE | 1 |
| Arnold, I | 1 |
| Sawaki, M | 1 |
| Mukai, H | 1 |
| Tokudome, N | 1 |
| Nakayama, T | 1 |
| Taira, N | 1 |
| Mizuno, T | 1 |
| Yamamoto, Y | 1 |
| Horio, A | 1 |
| Watanabe, T | 1 |
| Uemura, Y | 1 |
| Ohashi, Y | 1 |
| Hawkes, EA | 1 |
| Okines, AF | 1 |
| Plummer, C | 1 |
| Cunningham, D | 1 |
| Appel, JM | 1 |
| Zerahn, B | 1 |
| Møller, S | 1 |
| Christensen, HM | 1 |
| Søgaard, P | 1 |
| Ejlertsen, B | 1 |
| Fogh-Andersen, N | 1 |
| Jensen, BV | 1 |
| Nielsen, DL | 1 |
| Shah, SM | 1 |
| Drage, MG | 1 |
| Lichtman, AH | 1 |
| Haddad, RI | 1 |
| Bonneterre, J | 1 |
| Roché, H | 1 |
| Kerbrat, P | 1 |
| Fumoleau, P | 1 |
| Goudier, MJ | 1 |
| Fargeot, P | 1 |
| Montcuquet, P | 1 |
| Clavère, P | 1 |
| Barats, JC | 1 |
| Monnier, A | 1 |
| Veyret, C | 1 |
| Datchary, J | 1 |
| Van Praagh, I | 1 |
| Chapelle-Marcillac, I | 1 |
| Ventura, GJ | 1 |
| Meydan, N | 1 |
| Kundak, I | 1 |
| Yavuzsen, T | 1 |
| Oztop, I | 1 |
| Barutca, S | 1 |
| Yilmaz, U | 1 |
| Alakavuklar, MN | 1 |
| Branca, MA | 1 |
| Ishizaki, A | 1 |
| Katayama, K | 1 |
| Negishi, T | 1 |
| Kamisaka, K | 1 |
| Kawashiro, N | 1 |
| Kawana, M | 1 |
| Ganz, PA | 1 |
| Hussey, MA | 1 |
| Moinpour, CM | 1 |
| Unger, JM | 1 |
| Hutchins, LF | 1 |
| Dakhil, SR | 2 |
| Giguere, JK | 1 |
| Goodwin, JW | 1 |
| Martino, S | 2 |
| Albain, KS | 1 |
| Perez, EA | 1 |
| Suman, VJ | 1 |
| Davidson, NE | 1 |
| Sledge, GW | 1 |
| Kaufman, PA | 1 |
| Hudis, CA | 1 |
| Gralow, JR | 1 |
| Ingle, JN | 1 |
| Winer, EP | 1 |
| Gelmon, KA | 1 |
| Gersh, BJ | 1 |
| Jaffe, AS | 1 |
| Rodeheffer, RJ | 1 |
| Loprinzi, CL | 1 |
| Carbone, PP | 1 |
| Tormey, DC | 1 |
| Rosenbaum, PR | 1 |
| Caldwell, W | 1 |
| Kline, JC | 1 |
| Steeves, RA | 1 |
| Ramirez, G | 1 |
| Ciubra-Niczewska, E | 1 |
| Jelić, S | 1 |
| Radulović, S | 1 |
| Nesković-Konstantinović, Z | 1 |
| Kreacić, M | 1 |
| Ristović, Z | 1 |
| Bosnjak, S | 1 |
| Milanović, N | 1 |
| Vuletić, L | 1 |
| Schöber, C | 1 |
| Papageorgiou, E | 1 |
| Harstrick, A | 1 |
| Bokemeyer, C | 1 |
| Mügge, A | 1 |
| Stahl, M | 1 |
| Wilke, H | 1 |
| Poliwoda, H | 1 |
| Hiddemann, W | 1 |
| Köhne-Wömpner, CH | 1 |
| Lichinitser, MP | 1 |
| Vyshinskaia, GV | 1 |
| Min'kov, ED | 1 |
| Nakhalova, TA | 1 |
| Odzharova, AA | 1 |
| Garin, AM | 1 |
| Swain, SM | 3 |
| Whaley, FS | 2 |
| Gerber, MC | 2 |
| Weisberg, S | 1 |
| York, M | 1 |
| Spicer, D | 1 |
| Jones, SE | 1 |
| Wadler, S | 1 |
| Desai, A | 1 |
| Vogel, C | 1 |
| Speyer, J | 1 |
| Mittelman, A | 1 |
| Reddy, S | 1 |
| Pendergrass, K | 1 |
| Velez-Garcia, E | 1 |
| Ewer, MS | 2 |
| Bianchine, JR | 2 |
| Gams, RA | 2 |
| Dhingra, K | 1 |
| Frye, D | 1 |
| Newman, RA | 1 |
| Walters, R | 1 |
| Theriault, R | 1 |
| Fraschini, G | 1 |
| Smith, T | 1 |
| Buzdar, A | 1 |
| Hortobagyi, GN | 2 |
| David, JS | 1 |
| Gueugniaud, PY | 1 |
| Hepp, A | 1 |
| Gaussorgues, P | 1 |
| Petit, P | 1 |
| Bogolioubov, A | 1 |
| Keefe, DL | 1 |
| Groeger, JS | 1 |
| Schwetz, BA | 1 |
| Rubens, RD | 1 |
| Begent, RH | 1 |
| Knight, RK | 1 |
| Sexton, SA | 1 |
| Hayward, JL | 1 |
| Buzdar, AU | 2 |
| Blumenschein, GR | 2 |
| Gutterman, JU | 1 |
| Tashima, CK | 1 |
| Smith, TL | 2 |
| Campos, LT | 1 |
| Wheeler, WL | 1 |
| Hersh, EM | 1 |
| Freireich, EJ | 1 |
| Gehan, EA | 1 |
| Farndon, JR | 1 |
| Nemoto, T | 1 |
| Rosner, D | 1 |
| Diaz, R | 1 |
| Dao, T | 1 |
| Sponzo, R | 1 |
| Cunningham, T | 1 |
| Horton, J | 1 |
| Simon, R | 1 |
| Aitini, E | 1 |
| Cavazzini, G | 1 |
| Cantore, M | 1 |
| Rabbi, C | 1 |
| Rivera, A | 1 |
| Togliani, B | 1 |
| Di Marco, A | 1 |
| Smerieri, F | 1 |
| Buzzoni, R | 1 |
| Bonadonna, G | 1 |
| Valagussa, P | 1 |
| Zambetti, M | 1 |
| Sorace, RA | 1 |
| Bagley, CS | 1 |
| Danforth, DN | 1 |
| Bader, J | 1 |
| Wesley, MN | 1 |
| Steinberg, SM | 1 |
| Lippman, ME | 1 |
| Chaudary, S | 1 |
| Song, SY | 1 |
| Jaski, BE | 1 |
| Speyer, JL | 1 |
| Green, MD | 1 |
| Kramer, E | 1 |
| Rey, M | 1 |
| Sanger, J | 1 |
| Ward, C | 1 |
| Dubin, N | 1 |
| Ferrans, V | 1 |
| Stecy, P | 1 |
| Zeleniuch-Jacquotte, A | 1 |
| Jurga, L | 1 |
| Ponist, J | 1 |
| Jonás, P | 1 |
| Berc, A | 1 |
| Misurová, E | 1 |
| Posner, LE | 1 |
| Dukart, G | 1 |
| Goldberg, J | 1 |
| Bernstein, T | 1 |
| Cartwright, K | 1 |
| Marcus, C | 1 |
| Bruckner, HW | 1 |
| Creasey, WA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Multinational Phase II Study to Assess the Clinical Safety and Feasibility of Trastuzumab Emtansine Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage HER2-positive Breast Ca[NCT01196052] | Phase 2 | 153 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Late Cardiac Evaluation of the Three Arm Belgian Trial A Phase III Randomized Trial Involving Node-positive Early Breast Cancer Patients With a Long Median Follow-up (~ 15 Years)[NCT01554943] | Phase 2 | 73 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients Who Receiving Radical Concurrent Chemoradiotherapy and Immunotherapy: a Prospective, Randomized Controlled, Multicenter P[NCT04980716] | Phase 3 | 524 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
| Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405] | 97 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Withdrawal of analysis study Partner.) | |||
| Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long-Term Incidence of Clinical Cardiotoxicity in Women With Breast Cancer, A Prospective Randomized Study: The Cardio-Oncology Breast Cancer Study (COBC)[NCT02571894] | 320 participants (Anticipated) | Interventional | 2014-07-31 | Active, not recruiting | |||
| Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane in Patients With Breast Cancer[NCT03930680] | Phase 1 | 25 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
| A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer[NCT00001338] | Phase 3 | 65 participants | Interventional | 1993-06-30 | Completed | ||
| Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer[NCT00001239] | Phase 2 | 100 participants | Interventional | 1989-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01196052)
Timeframe: From the start to the end of radiotherapy treatment (up to 51 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 94.7 |
Participants were to receive up to a total of 17 cycles of trastuzumab emtansine. If trastuzumab was given concurrently with either the optional docetaxel or optional radiation, then the number of 3-week cycles of trastuzumab therapy was subtracted from the planned 17 cycles of trastuzumab emtansine therapy. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 82.4 |
(NCT01196052)
Timeframe: From the start to the end of concurrent hormonal therapy (up to 51 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 69.4 |
(NCT01196052)
Timeframe: From the start to the end of concurrent radiotherapy (up to 51 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 94.9 |
A cardiac event was defined as death from a cardiac cause or severe congestive failure (New York Heart Association [NYHA] Class III or IV) with a decrease in left ventricular ejection fraction (LVEF) of ≥ 10% from Baseline to an LVEF of < 50%. (NCT01196052)
Timeframe: Baseline to 12 weeks after the start of trastuzumab emtansine treatment
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 0 |
Pathological complete response was defined as the absence of invasive neoplastic cells at microscopic examination of the primary tumor and lymph nodes after surgery following primary systemic therapy. Pathological complete response was evaluated in participants treated with neoadjuvant therapy doxorubicin/cyclophosphamide-5-fluorouracil/epirubicin/cyclophosphamide followed by 1 or more doses of trastuzumab emtansine and who underwent surgery. (NCT01196052)
Timeframe: Day of surgery
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 56.0 |
The following percentages of participants are reported: At least 1 adverse event while receiving T-DM1; at least 1 serious adverse event while receiving T-DM1; an adverse event leading to discontinuation, dose delay, or dose reduction of trastuzumab emtansine treatment; symptomatic cardiac dysfunction; and asymptomatic decline in left ventricular ejection fraction (LVEF). An asymptomatic LVEF decline was defined as a LVEF < 50% and a maximum decrease ≥ 10% from Baseline. The percentage of participants who died is reported. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)
| Intervention | Percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| At least 1 adverse event (AE) | At least 1 serious adverse event | An AE leading to treatment discontinuation | An AE leading to dose delay | An AE leading to dose reduction | Symptomatic cardiac dysfunction | An asymptomatic decline in LVEF | Deaths | |
| Trastuzumab Emtansine | 98.6 | 10.1 | 13.5 | 29.1 | 21.6 | 0.0 | 2.7 | 0 |
5 reviews available for fluorouracil and Cardiac Failure
| Article | Year |
|---|---|
Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Cardiovascula | 2013 |
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.
Topics: Anthracyclines; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Cardiotoxicity; Fluorourac | 2016 |
[Drugs which cause heart failure and cardiotoxicity].
Topics: Anthracyclines; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agen | 2007 |
Circulatory shock.
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Anthracyclines; Antineoplastic Agents; Carcinoid Tu | 2001 |
Profound, yet reversible, heart failure secondary to 5-fluorouracil.
Topics: Adult; Aged; Female; Fluorouracil; Heart Failure; Humans | 1988 |
18 trials available for fluorouracil and Cardiac Failure
| Article | Year |
|---|---|
Effect of Breast Irradiation on Cardiac Disease in Women Enrolled in BCIRG-001 at 10-Year Follow-Up.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Card | 2017 |
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2015 |
Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2015 |
Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2011 |
Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2004 |
Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2008 |
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemo | 2008 |
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1997 |
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1997 |
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1997 |
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1997 |
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1997 |
Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 1995 |
Combined cytotoxic and progestogen therapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cycloph | 1978 |
Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy.
Topics: Adrenalectomy; Aged; Bone Marrow; Breast Neoplasms; Cyclophosphamide; Digestive System; Doxorubicin; | 1978 |
A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 1992 |
Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1991 |
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1991 |
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Tolerance; Female; Fluorouracil; | 1988 |
Mitoxantrone: an overview of safety and toxicity.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Clini | 1985 |
31 other studies available for fluorouracil and Cardiac Failure
| Article | Year |
|---|---|
[A case in which XELOX plus bevacizumab chemotherapy was effective in an elderly patient with heart failure and multiple liver metastases after sigmoidectomy].
Topics: Abdominal Abscess; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Use of extracorporeal membrane oxygenation for mechanical circulatory support in a patient with 5-fluorouracil induced acute heart failure.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Cardiotoxicity; Colorectal Neoplasms; Extrac | 2015 |
Bevacizumab safety in Japanese patients with colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2016 |
Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2016 |
5-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI.
Topics: Aged; Colorectal Neoplasms; Coronary Angiography; Diagnosis, Differential; Echocardiography; Female; | 2016 |
Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2008 |
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemo | 2008 |
A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Female; Fluorouracil; Heart Failure; Humans; Middle | 2009 |
Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2009 |
Case of epirubicin-induced cardiomyopathy in familial cardiomyopathy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cardiac | 2011 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Mono | 2011 |
Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Chemother | 2012 |
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread.
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Carb | 2012 |
Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clini | 2005 |
Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibri | 2005 |
BiDil raises questions about race as a marker.
Topics: Biomarkers; Black People; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihy | 2005 |
[Two cases with have a complication in cardiac function during chemotherapy with trastuzumab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2007 |
Aggressive combined modality therapy for advanced local-regional breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomegaly; Combine | 1984 |
[Cardiotoxicity of drugs used in the treatment of malignant neoplasms].
Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinatio | 1983 |
Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclo | 1995 |
Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Coronary Disease; | 1993 |
New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1995 |
[Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1996 |
Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Critical Care; Drug Monitoring; Drug Therapy, | 2000 |
From the Food and Drug Administration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Tr | 2001 |
Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, C | 1979 |
The carcinoid syndrome: methods of treatment and recent experience with hepatic artery ligation and infusion.
Topics: Female; Fluorouracil; Heart Failure; Hepatic Artery; Humans; Hydroxyindoleacetic Acid; Ileum; Intest | 1977 |
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1987 |
[Monitoring cardiotoxicity during antineoplastic chemotherapy].
Topics: Adult; Cardiomyopathies; Doxorubicin; Fluorouracil; Heart Failure; Humans; Middle Aged | 1987 |
Early and delayed clinical cardiotoxicity of doxorubicin.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclo | 1985 |
The administration of 5-fluorouracil by mouth.
Topics: Adenocarcinoma; Administration, Oral; Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Heart | 1974 |